Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures
Ayana T. Ruffin(University of Pittsburgh), Tullia C. Bruno(University of Pittsburgh), Angen Liu(University of Pittsburgh), Irina Abécassis(University of Pittsburgh), Robert Lafyatis(University of Pittsburgh Medical Center), Caleb Lampenfeld(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Sayali Onkar(University of Pittsburgh), Ryan J. Soose(University of Pittsburgh), Sheryl Kunning(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Anthony R. Cillo(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Zengbiao Qi(University of Pittsburgh), Dario A.A. Vignali(University of Pittsburgh), Steffi Oesterrich(University of Pittsburgh), Tracy Tabib(University of Pittsburgh)
Cited by 5
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Upper-Airway Stimulation for Obstructive Sleep Apnea
|New England Journal of Medicine|2014|1.2k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size
|Nature|1992|768
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688